Literature DB >> 21643644

Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.

Prashanth Kanagarajah1, Rajinikanth Ayyathurai, Daniel J Caruso, Christopher Gomez, Angelo E Gousse.   

Abstract

BACKGROUND: To evaluate the efficacy of intradetrusor botulinum toxin-A (BTX-A) in idiopathic overactive bladder patients (OAB) refractory to anti-muscarinic therapy, without detrusor overactivity (DOA) on urodynamics.
METHODS: Patients with refractory idiopathic OAB without DOA on urodynamics were prospectively enrolled. Subjects completed a 3-day voiding diary (3-VD), urogenital distress inventory-6 questionnaire (UDI-6) and graded their quality of life on a 10-cm visual analog scale (VAS) prior to study enrollment and at week 12 postinjection. All patients underwent multichannel urodynamics at study enrollment and 12 weeks postinjection. Improvement was analyzed based on 3-VD, UDI-6 questionnaire, VAS scores, and urodynamic parameters at week 12 postinjection compared to study enrollment.
RESULTS: The study included 32 patients. Mean ± SD age was 56 ± 16. There were 27 women and 5 men. Nineteen patients had OAB without incontinence (OAB-dry) and 13 patients had OAB with incontinence (OAB-wet). In OAB-dry patients, mean ± SD urinary frequency dropped from 24 ± 11 to 10 ± 4 by week 12. In OAB-wet patients, mean ± SD urge incontinence episodes dropped from 7.9 ± 5 to 0 ± 2.6 by week 12. Mean UDI-6 and VAS scores improved significantly in both groups by week 12 (P = 0.0001). On comparing urodynamic parameters, OAB-wet patients showed significant decrease in maximum detrusor pressure during the voiding phase at week 12 compared to baseline values (P = 0.02).
CONCLUSIONS: Refractory idiopathic OAB patients without DOA on urodynamics may benefit from intradetrusor BTX-A.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21643644     DOI: 10.1007/s11255-011-9979-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  25 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies.

Authors:  Werner Schäfer; Paul Abrams; Limin Liao; Anders Mattiasson; Francesco Pesce; Anders Spangberg; Arthur M Sterling; Norman R Zinner; Philip van Kerrebroeck
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

3.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

Review 4.  Detrusor overactivity: an overview.

Authors:  Kiran Ashok; Alex Wang
Journal:  Arch Gynecol Obstet       Date:  2010-02-27       Impact factor: 2.344

5.  Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection.

Authors:  Brian L Cohen; Rolando Rivera; Paholo Barboglio; Angelo Gousse
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

6.  Prevalence of the overactive bladder among Iranian women based on the International Continence Society definition: a population-based study.

Authors:  Mohammad Reza Safarinejad
Journal:  Int Urol Nephrol       Date:  2008-06-19       Impact factor: 2.370

7.  Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.

Authors:  Brian L Cohen; Paholo Barboglio; Dinorah Rodriguez; Angelo E Gousse
Journal:  Neurourol Urodyn       Date:  2009       Impact factor: 2.696

Review 8.  Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety.

Authors:  Michele Spinelli; Karl-Dietrich Sievert
Journal:  Eur Urol       Date:  2008-02-08       Impact factor: 20.096

9.  Comparison of ambulatory versus conventional urodynamics in females with urinary incontinence.

Authors:  Fulya Dokmeci; Murat Seval; Haydar Gok
Journal:  Neurourol Urodyn       Date:  2010-04       Impact factor: 2.696

10.  Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity.

Authors:  Arun Sahai; Christopher Dowson; Mohammad Shamim Khan; Prokar Dasgupta
Journal:  Urology       Date:  2009-12-29       Impact factor: 2.649

View more
  9 in total

1.  What is the true catheterization rate after intravesical onabotulinumtoxinA injection?

Authors:  Devin N Patel; Juzar Jamnagerwalla; Justin Houman; Jennifer T Anger; Karyn S Eilber
Journal:  Int Urogynecol J       Date:  2017-08-14       Impact factor: 2.894

Review 2.  Randomized clinical trials assessing third-line therapies to treat non-neurogenic overactive bladder syndrome: a review about methodology.

Authors:  Pierre-Luc Dequirez; Xavier Biardeau
Journal:  Int Urogynecol J       Date:  2021-03-26       Impact factor: 2.894

Review 3.  Management of OAB in those over age 65.

Authors:  Ricardo Natalin; Fabio Lorenzetti; Miriam Dambros
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

4.  Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study.

Authors:  Gaetano De Rienzo; Paolo Minafra; Ester Iliano; Enrico Finazzi Agrò; Maurizio Serati; Alessandro Giammò; Francesco Paolo Bianchi; Elisabetta Costantini; Pasquale Ditonno
Journal:  Neurourol Urodyn       Date:  2021-10-19       Impact factor: 2.367

Review 5.  Refractory overactive bladder: a common problem?

Authors:  Ulrich Schwantes; Joachim Grosse; Andreas Wiedemann
Journal:  Int Urogynecol J       Date:  2015-03-20       Impact factor: 2.894

Review 6.  Overactive bladder - 18 years - Part II.

Authors:  Jose Carlos Truzzi; Cristiano Mendes Gomes; Carlos A Bezerra; Ivan Mauricio Plata; Jose Campos; Gustavo Luis Garrido; Fernando G Almeida; Marcio Augusto Averbeck; Alexandre Fornari; Anibal Salazar; Arturo Dell'Oro; Caio Cintra; Carlos Alberto Ricetto Sacomani; Juan Pablo Tapia; Eduardo Brambila; Emilio Miguel Longo; Flavio Trigo Rocha; Francisco Coutinho; Gabriel Favre; Jose Antonio Garcia; Juan Castano; Miguel Reyes; Rodrigo Eugenio Leyton; Ruiter Silva Ferreira; Sergio Duran; Vanda Lopez; Ricardo Reges
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

Review 7.  Common theme for drugs effective in overactive bladder treatment: inhibition of afferent signaling from the bladder.

Authors:  Brandy Hood; Karl-Erik Andersson
Journal:  Int J Urol       Date:  2012-10-17       Impact factor: 3.369

8.  New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA.

Authors:  Karl-Erik Andersson
Journal:  Ther Clin Risk Manag       Date:  2013-04-18       Impact factor: 2.423

9.  Botulinum toxin type A induces changes in the chemical coding of substance P-immunoreactive dorsal root ganglia sensory neurons supplying the porcine urinary bladder.

Authors:  Agnieszka Bossowska; Ewa Lepiarczyk; Urszula Mazur; Paweł Janikiewicz; Włodzimierz Markiewicz
Journal:  Toxins (Basel)       Date:  2015-11-16       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.